Patrick A. Baeuerle

Patrick Baeuerle (born 24 November 1957) is a German-based molecular biologist, immunologist, professor and a biopharmaceutical entrepreneur. Baeuerle is known for his work on tyrosine sulfation of proteins,[1] transcription factor NF-kappaB,[2] and the development of bispecific T-cell engaging antibodies for therapy of cancer.[3]

Patrick A. Baeuerle
Born
Patrick Alexander Baeuerle

(1957-11-24) November 24, 1957
Friedrichshafen, Germany
OccupationMolecular biologist, Immunologist, Entrepreneur and professor
Years active1986-present

Education

Baeuerle earned his diploma in biology from University of Konstanz, Germany. He received his Ph.D. in biochemistry with summa cum laude, from the Ludwig Maximilian University of Munich. His postdoctoral training was with the Nobel Laureate David Baltimore at the Whitehead Institute at Massachusetts Institute of Technology, Cambridge, MA.[4][5]

Career

After his post-doctorate, Baeuerle led a research group at Gene Center in Martinsried, Germany. In 1993, he became the professor of molecular biology, and was and the chairman at the medical faculty of Freiburg University, Germany.[6]

Between 1996 and 2015, he served as head of drug discovery at Tularik Inc.,[7][8] as chief scientific officer at Micromet Inc.,[9][10] and as a vice president research for Amgen Inc.[11] in Munich, Germany.

Baeuerle is the co-founder of the companies, iOmx AG, Harpoon Inc,[12] TCR2 Inc,[10] Maverick Inc, and Cullinan LLC. He is one of the Managing directors at MPM capital, which is a Cambridge-based venture capital firm.[11][13]

Research Activities

Tyrosine Sulfation

In 1987, Baeuerle showed that tyrosine sulfation is a frequent modification of secretory proteins that is added in the trans-Golgi compartment.[14][1]

Transcription factor NF-kappaB

Baeuerle deciphered the canonical pathway by which transcription factor NF-kappaB is activated and first described inhibitory subunit I-kappaB and the p65/RelA subunit.[2][15] Baeuerle is said to be one of the inventors of the controversial NF-kappaB.[16][17] He along with his team showed that NF-kappaB is an oxidative stress-responsive transcription factor and described a functional role of NF-kappaB in the nervous system.[18][19]

Cancer Therapy

Baeuerle lead the development of BiTE antibody Blincyto® (blinatumomab; AMG 103)[20] which is approved by the US FDA for treatment of relapsed/refractory acute lymphoblastic leukemia.[21][22] He has invented various antibody-based constructs that are designed to engage cytotoxic T cells for lysis of cancer cells.[23]

gollark: It just relies on compiler magic for everything, and it's controlled dictatorially by whatshisname.
gollark: Elm removed CUSTOM OPERATORS!
gollark: <:bees:724389994663247974> Elm.
gollark: Via typeclasses.
gollark: Although Haskell will happily let an operator use multiple different types.

References
  1. Baeuerle, P. A.; Huttner, W. B. (December 1987). "Tyrosine sulfation is a trans-Golgi-specific protein modification". The Journal of Cell Biology. 105 (6 Pt 1): 2655–2664. doi:10.1083/jcb.105.6.2655. ISSN 0021-9525. PMC 2114704. PMID 3121635.
  2. P A Baeuerle; Henkel, and T. (1994). "Function and Activation of NF-kappaB in the Immune System". Annual Review of Immunology. 12 (1): 141–179. doi:10.1146/annurev.iy.12.040194.001041. PMID 8011280.
  3. Baeuerle, Patrick A.; Reinhardt, Carsten (2009-06-15). "Bispecific T-Cell Engaging Antibodies for Cancer Therapy". Cancer Research. 69 (12): 4941–4944. doi:10.1158/0008-5472.CAN-09-0547. ISSN 0008-5472. PMID 19509221.
  4. . Patrick A. Baeuerle, David Baltimore, Whitehead Institute For Biomedical Research. "Patent WO1989008147A1 - ACTIVITION OF NF-kB PRECURSOR". Google Books. 1989-03-01.CS1 maint: others (link)
  5. Baeuerle, Patrick A.; Baltimore, David (1988-04-22). "Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-κB transcription factor". Cell. 53 (2): 211–217. doi:10.1016/0092-8674(88)90382-0. ISSN 0092-8674. PMID 3129195.
  6. Hall, Stephen S. (1997-11-23). "Success Is Like a Drug". The New York Times. ISSN 0362-4331. Retrieved 2017-10-04.
  7. "Two Distinct Career Paths Offer Clear Choices". The Scientist. Retrieved 2017-10-04.
  8. "Reinventing the Antibody". The Scientist. Retrieved 2017-10-04.
  9. Perkel, Jeffrey (2008-08-14). "New Lymphoma Drug Shows Promise". ISSN 0190-8286. Retrieved 2017-10-04.
  10. "TCR2 Therapeutics Unveils New Cancer Therapy Approach and $44.5M Round | Xconomy". Xconomy. 2016-12-08. Retrieved 2017-10-04.
  11. "Amgen vet Patrick Baeuerle inspires a $45M round from A-list VCs for a next-gen I/O drug platform". endpts.com. Retrieved 2017-10-04.
  12. Gormley, Brian (2017-05-25). "Harpoon Therapeutics Snares $45 Million Series B for Prostate Cancer Treatment". Wall Street Journal. ISSN 0099-9660. Retrieved 2017-10-04.
  13. "MPM Names Drug Developer Patrick Baeuerle Managing Director". Wall Street Journal. 2015-03-12. ISSN 0099-9660. Retrieved 2017-10-04.
  14. "Tyrosine sulfation of yolk proteins 1, 2, and 3 in Drosophila melanogaster (PDF Download Available)". ResearchGate. Retrieved 2017-10-04.
  15. "IkappaB: A Specific Inhibitor of the NF-kappaB Transcription Factor - ProQuest". search.proquest.com. Retrieved 2017-10-04.
  16. , Baltimore, David; Ranjan Sen & Phillip A. Sharp, "Nuclear factors associated with transcriptional regulation"
  17. "Espacenet - Bibliographic data". worldwide.espacenet.com. Retrieved 2017-10-04.
  18. "Patrick A. Baeuerle - Google Scholar Citations". scholar.google.de. Retrieved 2017-10-04.
  19. Schreck, Ralf; Albermann, Kaj; Baeuerle, Patrick A. (1992-01-01). "Nuclear Factor Kb: An Oxidative Stress-Responsive Transcription Factor of Eukaryotic Cells (A Review)". Free Radical Research Communications. 17 (4): 221–237. doi:10.3109/10715769209079515. ISSN 8755-0199. PMID 1473734.
  20. Baeuerle, Patrick A.; Kufer, Peter; Bargou, Ralf (February 2009). "BiTE: Teaching antibodies to engage T-cells for cancer therapy". Current Opinion in Molecular Therapeutics. 11 (1): 22–30. ISSN 2040-3445. PMID 19169956.
  21. Swaminathan, Nikhil. "Antibody Drug Unleashes Tumor-Killer T Cells". Scientific American. Retrieved 2017-10-04.
  22. Editor, Roger Highfield, Science (2008-08-14). "Patients 'free from cancer' after immune-boost treatment". Daily Telegraph. ISSN 0307-1235. Retrieved 2017-10-04.CS1 maint: extra text: authors list (link)
  23. Baeuerle, Patrick A.; Reinhardt, Carsten (2009-06-15). "Bispecific T-cell engaging antibodies for cancer therapy". Cancer Research. 69 (12): 4941–4944. doi:10.1158/0008-5472.CAN-09-0547. ISSN 1538-7445. PMID 19509221.
  1. University of Munich
  2. Micromet, Inc.
  3. University of Konstanz
  4. Max-Planck Institute of Molecular Cell Biology and Genetics
  5. Max-Planck Institute for Neurobiology
  6. EMBL
  7. Whitehead Institute
  8. GeneCentre
  9. University of Freiburg
  10. NF-kappa B (516) patent
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.